MESOBLAST WINS DELOITTE TECH FAST 50 LEADERSHIP & ENTERPRISE GROWTH AWARD New York, USA: November 19 and Melbourne, Australia: November 20, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the...
Mesoblast Wins Deloitte Tech Fast 50 Leadership Award
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The award highlights Mesoblast's successful transition to a commercial-stage biotechnology company following the U.S. launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy. The Chief Executive expressed pride in the recognition, emphasizing the company's commitment to sustainable growth and delivering long-term value for shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Mesoblast
- Mesoblast Showcased at ASX Investor Day
- CEO Presentation ASX Investor Day
- Initial Director's Interest Notice
- Results of Meeting
- CEO Presentation to 2026 Annual General Meeting
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast